John A Hartley Selected Research

pyrrolo(2,1-c)(1,4)benzodiazepine

1/2022	Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
1/2021	Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
1/2020	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
1/2020	The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
1/2019	Potentiation of PBD Dimers by Lipophilicity Manipulation.
10/2018	Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
11/2016	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John A Hartley Research Topics

Disease

59	Neoplasms (Cancer) 01/2022 - 07/2003
7	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 03/2004
5	Leukemia 01/2018 - 06/2003
4	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 04/2011
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 06/2015
4	Melanoma (Melanoma, Malignant) 08/2015 - 09/2004
4	Breast Neoplasms (Breast Cancer) 12/2013 - 09/2004
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2017
2	Adenocarcinoma 01/2020 - 12/2015
2	Prostatic Neoplasms (Prostate Cancer) 10/2018 - 04/2006
2	Hypoxia (Hypoxemia) 02/2018 - 11/2004
2	Lymphoma (Lymphomas) 01/2018 - 11/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 08/2005
2	Glioma (Gliomas) 07/2014 - 09/2004
2	Multiple Myeloma 09/2012 - 07/2002
1	Residual Neoplasm 10/2021
1	Cytokine Release Syndrome 10/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020
1	Liver Neoplasms (Liver Cancer) 10/2019
1	Autoimmune Diseases (Autoimmune Disease) 10/2017
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2016
1	Colorectal Neoplasms (Colorectal Cancer) 06/2016
1	Circulating Neoplastic Cells 01/2016
1	Disease Progression 01/2016

Drug/Important Bio-Agent (IBA)

29	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 07/2002
9	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 11/2015
9	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 03/2004
7	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2022 - 11/2016
5	ProdrugsIBA 10/2019 - 11/2004
5	ErbB Receptors (EGF Receptor)IBA 06/2016 - 10/2004
4	Biomarkers (Surrogate Marker)IBA 11/2021 - 04/2015
4	Pharmaceutical PreparationsIBA 01/2020 - 02/2006
4	1,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)IBA 06/2011 - 09/2004
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 04/2015
3	Proteins (Proteins, Gene)FDA Link 03/2015 - 09/2004
3	Gefitinib (Iressa)FDA Link 12/2013 - 10/2004
3	Melphalan (Alkeran)FDA LinkGeneric 09/2012 - 07/2002
3	Etoposide (VP 16)FDA LinkGeneric 11/2009 - 10/2004
2	vandetanib (ZD6474)IBA 01/2022 - 10/2019
2	olaparibIBA 01/2022 - 02/2018
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 11/2021 - 03/2015
2	N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA 02/2018 - 12/2015
2	A-factor (Streptomyces)IBA 10/2017 - 07/2010
2	Trastuzumab (Herceptin)FDA Link 01/2017 - 11/2009
2	Gemcitabine FDA Link 12/2015 - 10/2010
2	PoisonsIBA 12/2013 - 09/2004
2	PlatinumIBA 09/2012 - 10/2010
2	Drug CombinationsIBA 06/2011 - 07/2010
2	Nylons (Nylon)IBA 05/2010 - 01/2007
2	Mechlorethamine (Nitrogen Mustard)FDA Link 05/2007 - 11/2004
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	monomethyl auristatin EIBA 01/2022
1	auristatinIBA 01/2022
1	Formaldehyde (Formol)FDA Link 11/2021
1	ParaffinIBA 11/2021
1	SteroidsIBA 10/2021
1	Chimeric Antigen ReceptorsIBA 10/2021
1	LigandsIBA 09/2021
1	Peptides (Polypeptides)IBA 01/2020
1	Cell Surface ReceptorsIBA 01/2020
1	futuximabIBA 01/2020
1	IntegrinsIBA 01/2020
1	GlucuronidaseIBA 10/2019
1	Histones (Histone)IBA 10/2018
1	AntigensIBA 10/2018
1	glutamate carboxypeptidaseIBA 10/2018
1	MEDI3726IBA 10/2018
1	Adenosine Diphosphate (ADP)IBA 02/2018
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 02/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2018
1	TH 302IBA 02/2018
1	CD19 AntigensIBA 01/2018
1	loncastuximab tesirineIBA 01/2018
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2018
1	Tubulin ModulatorsIBA 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	Interleukin-2 (IL2)IBA 10/2017
1	ChromatinIBA 01/2017
1	rovalpituzumab tesirineIBA 11/2016
1	Cetuximab (Erbitux)FDA Link 06/2016
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2016
1	ElementsIBA 01/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 12/2015
1	Caspase 3 (Caspase-3)IBA 12/2015
1	NucleosidesIBA 12/2015
1	Antineoplastic Agents (Antineoplastics)IBA 11/2015
1	naphthalenediimideIBA 06/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2015
1	p38 Mitogen-Activated Protein KinasesIBA 06/2015

Therapy/Procedure

18	Therapeutics 11/2021 - 10/2004
7	Drug Therapy (Chemotherapy) 11/2015 - 09/2004
2	Stem Cell Transplantation 10/2021 - 07/2002
1	Aftercare (After-Treatment) 01/2022
1	Castration 10/2018
1	Immunotherapy 10/2017
1	Adjuvant Chemotherapy 01/2017